To investigate the potential role of serum VEGFA in screening the population that may benefit from chemotherapy, we previously launched a prospective cohort study in highly malignant SCLC and revealed the unique ability of VEGFA to predict first-line chemotherapeutic efficacy and survival in patients with this kind of disease (37). The gene discussed is VEGFA; the disease is small cell lung carcinoma.